Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

NCT02736617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions

DRUG: Ibrutinib
BIOLOGICAL: Obinutuzumab

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]